Immediate Impact
4 from Science/Nature 56 standout
Citing Papers
Covalent targeted radioligands potentiate radionuclide therapy
2024 StandoutNature
[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study
2024 Standout
Works of W A Macdonald being referenced
Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: Phase II study evaluating the activity of 177Lu-Octreotate peptide receptor radionuclide therapy (LuTate PRRT) and capecitabine, temozolomide CAPTEM)—First results for pancreas and updated midgut neuroendocrine tumors (pNETS, mNETS).
2020
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| W A Macdonald | 228 | 93 | 94 | 112 | 106 | 51 | 816 | |
| Daniel I. Brooks | 75 | 108 | 61 | 37 | 65 | 61 | 929 | |
| Tomoaki Matsumoto | 346 | 64 | 35 | 73 | 75 | 33 | 901 | |
| Robin L. Smith | 127 | 46 | 15 | 31 | 60 | 33 | 768 | |
| T. Nagasaka | 73 | 67 | 69 | 44 | 14 | 53 | 826 | |
| Hughes | 56 | 51 | 44 | 32 | 35 | 43 | 947 | |
| Silvia Mazzola | 199 | 9 | 53 | 114 | 71 | 61 | 830 | |
| W. S. Monkhouse | 31 | 22 | 54 | 26 | 190 | 31 | 808 | |
| B. A. Kakulas | 394 | 128 | 124 | 68 | 51 | 65 | 897 | |
| Sue Ann Thompson | 119 | 14 | 94 | 67 | 36 | 49 | 888 | |
| David Marshall | 63 | 86 | 99 | 78 | 119 | 42 | 951 |
All Works
Loading papers...